TSXV:BTI.H - Post by User
Comment by
BearDownAZon Feb 05, 2016 3:56pm
102 Views
Post# 24530027
RE:RE:RE:INTERESTING POST FROM OTHER BOAR RE BBB IN PART
RE:RE:RE:INTERESTING POST FROM OTHER BOAR RE BBB IN PARTDigitel, nice find. That is an interesting research finding of engineered zinc finger-based articifical transcription factors able to cross the BBB. I'll try to look at the paper more closely as time allows.
As for regardless who wrote: "
Great...now we have an orally active version of trancendpep to go up against???. ....while they will be or are allready in clinical trials.... Were still sitting here talking about possible valuation ??? Does anyone here find it concerning reagrding the post jkj193741 posted? ?... That somebody has created a possible pill version of our holy grail?...just like that ?"
That is far from correct regardless. ONT-380 is an orally active, reversible and selective small-molecule HER2 inhibitor, not a peptide carrier like MTfp/Transcendpep. Yes, ONT-380 is in clinical trials. They just started recruing for a Phase 2 that won't be completed until 2019. The only relevance to Bioasis is that ONE of the SEVERAL applications of MTfp/Transcendpep that we know about is create a MTfp fusion protein with anti-HER2 antibodies (Herceptin/trastuzumab). So in this case, ONT-380 is a direct competitor with the Mtfp-Herceptin program because both treatments target the same molecule HER2 and are able to cross the BBB. ONT-380, like many small molecule inhibitors, can cross the BBB. What ONT-380 is not, however, is a trojan-horse/peptide-carrier that can be used to shuttle antibodies, enzymes, siRNAs, and other molecules across the BBB like Mtfp.
BearDownAZ